Recently, because of its indolent nature, it was proposed that the entity "noninvasive encapsulated follicular variant of papillary thyroid cancer" (NEFVPTC) be reclassified as "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP). 1 Several outcome studies in recent literature have demonstrated that adequately sampled NEFVPTCs have extremely low metastatic potential and risk of recurrence. In addition, there has been little change in mortality from thyroid carcinoma despite a nearly threefold increase in thyroid carcinoma incidence in the past 30 years. This increase in thyroid carcinoma diagnoses has been partially attributed to increased pathologists' awareness of NEFVPTCs. [2] [3] [4] [5] Prior to surgical resection, most thyroid nodules undergo fine-needle aspiration (FNA) and are classified using the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) into one of six categories. Each Bethesda category has a designated rate of malignancy (ROM) range ❚Table 1❚ and a recommended course of action based on previously published data of surgical resection diagnoses following thyroid FNAs. 6 The BSRTC, which includes category I (nondiagnostic [ found widespread acceptance and has been endorsed by the American Thyroid Association in its revised 2015 guidelines. 7 However, the reclassification of a malignant neoplasm to nonmalignant will alter the ROMs of the BSRTC categories, which may require updated management guidelines.
A handful of studies have acknowledged that the reclassification of NEFVPTC to NIFTP will change the ROMs and have noted that most preoperative FNAs of NIFTP fall in "indeterminate" categories (III-V) in the BSRTC. 8, 9 Our group has already anticipated this change and has begun to analyze the cytomorphologic features of NIFTP in comparison to other thyroid lesions on FNA. 10 However, there are few quantitative data detailing the ROM changes. To our knowledge, only four studies were previously published examining this change. Although the data remain scarce, all existing studies (including the present one) have noted a decrease in ROM across all BSRTC categories when applying the newly proposed classification. As expected, the most pronounced decreases in ROMs are noted in the "indeterminate" categories.
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Materials and Methods
The study protocol was approved by the New York University Institutional Review Board. All adult cases of thyroid FNAs with subsequent surgical resection pathology were identified over a 42-month period (January 2013 through June 2016) via a retrospective search of our laboratory information system. Pathology reports and histology slides of all encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) cases were reviewed. EFVPTC cases in which the entire tumor capsule interface was sampled and that met the criteria outlined by Nikiforov 1 (well-circumscribed or encapsulated nodule lacking the following: invasion through the capsule or into adjacent parenchyma, angioinvasion, lymph node metastases, features of other variants of papillary thyroid carcinoma (PTC), and tumor necrosis, with fewer than three mitoses per 10 highpower fields and a score of 2-3 out of 3 in the authors' proposed 3-point nuclear scoring scheme) were classified as NIFTP. EFVPTC cases that did not meet the criteria for NIFTP (demonstrating angioinvasion, lymphatic invasion, perineural invasion, extrathryoidal extension, invasion through tumor capsule, lymph node metastases, true papillae >1%, psammoma bodies, infiltrative border, tumor necrosis, or high mitotic activity) were classified as invasive EFVPTC and included in the malignant category. Cases were excluded if the nodule biopsied by FNA biopsy (FNAB) did not correspond to the surgically resected nodule, if the FNAB was performed more than 6 months prior to the resection, or if the patient was younger than 18 years.
The prevalence of NIFTP in each BSRTC category was determined. The ROM was calculated pre-and post-NIFTP nomenclature change for each BSRTC category: prenomenclature change, when NEFVPTC/NIFTP cases were considered a "malignant" subtype of PTC, and postnomenclature change, removing NEFVPTC/NIFTP from the malignant, PTC category and placing it in the "nonmalignant" category. Using SPSS version 23 (SPSS, 
Results
In total, 750 cases with FNA and corresponding surgical resection were identified. Within this group, there were 87 cases of NEFVPTC/NIFTP (87 unique nodules in 85 patients) and 21 cases of invasive EFVPTC. Of the patients with a diagnosis of NEFVPTC/NIFTP, 23 were male and 62 were female, with a mean age of 52 years (range, 24 to 82 years).
Of the 87 cases of NEFVPTC/NIFTP, 68% were called AUS/FLUS or FN/SFN on FNA. The pre-to postnomenclature ROM changes for each BSRTC category are shown in 
Discussion
EFVPTC historically represented up to 20% of all PTC cases and had been increasing in diagnostic incidence. [15] [16] [17] [18] [19] [20] The reclassification of many noninvasive cases of EFVPTC to NIFTP thus portends changes in treatment and potentially in presurgical FNA diagnosis of this lesion, especially given its increasing prevalence. How this reclassification will affect management algorithms and how it will be incorporated into thyroid cytopathology remains to be determined.
At our institution, the prevalence of NIFTP among those patients with FNA and subsequent surgical resection is 11.6%. The prevalence of NIFTP in surgically resected thyroid nodules varies across the literature, with recent studies at large academic institutions reporting a prevalence between 5% and 13%. [11] [12] [13] Although there is interinstitutional variability, our results fall within the range of recently reported prevalences. Our study corroborates the results of the four previous studies and adds valuable data to enumerate the changes in ROMs due to the recently proposed reclassification. Currently, the available ROM data (including ours) show that there are decreases across all BSRTC categories, with the following new ROM ranges for each BSRTC category ❚Table 2❚ and ❚Table 3❚: ND, 6.5% to 23.9% (∆, 0%-6.5%); benign, 2.5% to 7.1% (∆, 1%-7.8%); AUS/FLUS, 15.1% to 30% (∆, 2.3%-20%); FN/SFN, 10% to 37.5% (∆, 2.5%-28%); SFM, 45.7% to 65.8% (∆, 17%-41.5%); and PosM, 87% to 97% (∆, 3%-12.8%).
The previous (and current) studies have demonstrated statistically significant reductions in ROM in the three indeterminate BSRTC categories upon the reclassification of NIFTP. If NIFTP is to be accepted as a nonmalignant entity, then, as was done in the current version of the BSRTC, meta-analysis of several studies would be indicated to refine the implied ROM for each diagnostic category in upcoming versions of the BSRTC. [21] [22] [23] Like follicular adenomas, NIFTP nodules require surgical intervention and careful histologic evaluation to distinguish NIFTP from its invasive histomorphologic counterpart, invasive encapsulated follicular variant of papillary thyroid carcinoma (IFVPTC). In lieu of changing the ROMs for each BSRTC category, it has been suggested that alteration of the terminology from "risk of malignancy" to "risk of neoplasm" would keep NIFTP in the "neoplasm" category; however, this alteration would also shift follicular adenoma into the "risk of neoplasm" category in new calculations, potentially undermining the utility of the BSRTC in clinical decision making. 21 For those cases of NIFTP that are diagnosed as SFM preoperatively, recognition of the possibility of NIFTP and a lower ROM in that category may prompt a more conservative treatment plan (ie, lobectomy rather than total thyroidectomy). In addition, cytopathologists may adopt a shift in diagnostic practice-for example, when the possibility of NIFTP is suggested in a case with papillary nuclear features and predominantly microfollicular architecture, 10 the cytopathologist may opt to be more conservative in the Bethesda system diagnosis, with a note including both NIFTP and IFVPTC in the differential diagnosis. It remains to be seen how NIFTP will be incorporated into BSRTC. 21 In conclusion, our findings display a real change in ROM among the indeterminate Bethesda categories, in a large academic institution. Additional larger studies across multiple institutions are indicated to validate our findings. Our findings add particular value to the limited existing literature on the topic as the reclassification of NIFTP may lead to significant effects on the practice of thyroid cytopathology and clinical management. AUS/FLUS, atypia of undetermined significance/follicular lesion of undetermined significance; BSRTC, Bethesda System for Reporting Thyroid Cytopathology; FN/ SFN, follicular neoplasm/suspicious for follicular neoplasm; ND, nondiagnostic; NIFTP, noninvasive follicular thyroid neoplasm with papillary-like nuclear features; PosM, positive for malignancy; ROM, rate of malignancy; SFM, suspicious for malignancy.
